Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8⁺ and CD4⁺ T-cell responses with multiple specificities including a novel DR7-restricted epitope

P. BaumgaertnerLudwig Cancer Research Center, Department of Oncology, University of Lausanne, Switzerland

C. Costa NunesLudwig Cancer Research Center, Department of Oncology, University of Lausanne, Switzerland

A. CachotLudwig Cancer Research Center, Department of Oncology, University of Lausanne, Switzerland

H. Maby-El HajjamiLudwig Cancer Research Center, Department of Oncology, University of Lausanne, Switzerland;Department of Oncology, University Hospital Center (CHUV), Lausanne, Switzerland

L. CagnonDepartment of Oncology, University Hospital Center (CHUV), Lausanne, Switzerland

M. BraunLudwig Cancer Research Center, Department of Oncology, University of Lausanne, Switzerland

L. DerréUrology Research Unit, Urology Department, University Hospital Center (CHUV), Lausanne, Switzerland

J.-P. RivalsDepartment of Otorhinolaryngology – Head and Neck Surgery, CHUV, University of Lausanne, Switzerland

D. RimoldiLudwig Cancer Research Center, Department of Oncology, University of Lausanne, Switzerland

S. GnjaticTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA

S. Abed MaillardDepartment of Oncology, University Hospital Center (CHUV), Lausanne, Switzerland

P. Marcos MondéjarLudwig Cancer Research Center, Department of Oncology, University of Lausanne, Switzerland;Department of Oncology, University Hospital Center (CHUV), Lausanne, Switzerland

M. P. ProttiTumor Immunology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy;Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy

E. RomanoDepartment of Oncology, University Hospital Center (CHUV), Lausanne, Switzerland

O. MichielinLudwig Cancer Research Center, Department of Oncology, University of Lausanne, Switzerland;Department of Oncology, University Hospital Center (CHUV), Lausanne, Switzerland

P. RomeroLudwig Cancer Research Center, Department of Oncology, University of Lausanne, Switzerland;Department of Oncology, University Hospital Center (CHUV), Lausanne, Switzerland

D. E. SpeiserLudwig Cancer Research Center, Department of Oncology, University of Lausanne, Switzerland;Department of Oncology, University Hospital Center (CHUV), Lausanne, SwitzerlandCorrespondence[email protected] [email protected]

C. JandusLudwig Cancer Research Center, Department of Oncology, University of Lausanne, SwitzerlandCorrespondence[email protected] [email protected]

show all

Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8⁺ and CD4⁺ T-cell responses with multiple specificities including a novel DR7-restricted epitope

Articles from other publishers (39)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope

Citations (42)

Read on this site (3)

Articles from other publishers (39)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8⁺ and CD4⁺ T-cell responses with multiple specificities including a novel DR7-restricted epitope